GILBERT GODIN

Mr. Godin is a co-founder and the President and Chief Operating Officer of HLS Therapeutics Inc. (TSX:HLS),  a Canadian based, North American focused specialty pharmaceutical company.

Prior to co-founding HLS, Mr. Godin was CEO of Duchesnay USA where he created the team that brought Duchesnay’s first product to the US OBGYN market. Before that, Mr. Godin was Executive Vice President and Chief Operating Officer of Biovail Corporation; formerly Canada’s largest publicly traded pharmaceutical company. In that capacity, he oversaw Business Operations, R&D, Plant Operations, Regulatory Affairs, and Licensing until the merger of Biovail and Valeant Pharmaceutical International Inc. (TSX:VRX) at the end of 2010.  Prior to Biovail, Mr. Godin spent 7 years at MDS Pharma Services, leading a team of 4,000 scientists in 42 countries as President of the global Contractual Research Organization for the pharmaceutical market. Before joining MDS Pharma, Mr. Godin held Executive roles at Schering Plough in Canada and in Europe (France) where he directed the strategic and commercial deployment in the field of viral hepatitis, and at L’Oreal Healthcare in commercial and technical leadership roles.

Mr. Godin attended Sherbrooke University where he received a Bachelor in Mechanical Engineering in 1982 and the John Molson School of Business where he received a Master in Business Administration in 1992.